Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL

מאת Barr, Paul M., Saylors, Gene B., Spurgeon, Stephen E., Cheson, Bruce D., Greenwald, Daniel R., O’Brien, Susan M., Liem, Andre K. D., Mclntyre, Rosemary E., Joshi, Adarsh, Abella-Dominicis, Esteban, Hawkins, Michael J., Reddy, Anita, Di Paolo, Julie, Lee, Hank, He, Joyce, Hu, Jing, Dreiling, Lyndah K., Friedberg, Jonathan W.
הוצא לאור ב Blood (2016)

Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL - Interim Results of a Phase 3 Randomized, Double-blind Placebo-Contro...

מאת Zelenetz, Andrew D., Barrientos, Jacqueline C., Brown, Jennifer R., Coiffier, Bertrand, Delgado, Julio, Egyed, Miklós, Ghia, Paolo, Illés, Árpád, Jurczak, Wojciech, Marlton, Paula, Montillo, Marco, Morschhauser, Franck, Pristupa, Alexander S., Robak, Tadeusz, Sharman, Jeff P., Simpson, David, Smolej, Lukáš, Tausch, Eugen, Adewoye, Adeboye H., Dreiling, Lyndah K., Kim, Yeonhee, Stilgenbauer, Stephan, Hillmen, Peter
הוצא לאור ב Lancet Oncol (2017)

Risk Model for Overall Survival in Relapsed or Refractory Chronic Lymphocytic Leukaemia in the Era of Targeted Therapies

מאת Soumerai, Jacob D., Ni, Ai, Darif, Mohamed, Londhe, Anil, Xing, Guan, Mun, Yong, Kay, Neil E., Shanafelt, Tait D., Rabe, Kari G., Byrd, John C., Chanan-Khan, Asher A., Furman, Richard R., Hillmen, Peter, Jones, Jeffrey, Seymour, John F., Sharman, Jeffrey P., Ferrante, Lucille, Mobasher, Mehrdad, Stark, Thomas, Reddy, Vijay, Dreiling, Lyndah K., Bhargava, Pankaj, Howes, Angela, James, Danelle F., Zelenetz, Andrew D.
הוצא לאור ב Lancet Haematol (2019)